DNA X regains Nasdaq stockholders’ equity compliance after panel review
SONM•Panel monitor period extends through 2027
Mandatory panel monitor runs until Aug. 28, 2027, tightening consequences for any renewed equity shortfall.
A repeat breach would trigger a delisting determination with no option to submit a compliance plan or receive extra time.
Nasdaq compliance restored after panel review
Nasdaq hearings panel notified DNA X on Aug. 28, 2026 that it regained compliance with the $2.5 million stockholders’ equity rule.
Delisting risk remains if listing rules are breached
Securities remain at risk of delisting if the company fails to stay compliant with all Nasdaq listing rules through Nov. 18, 2026.
